Theratechnologies Inc (THTX) FinancialsTHTXTheratechnologies Inc

Theratechnologies Inc (THTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is EGRIFTA, accounting for 62.8% of total sales, equivalent to $11.13M. Another important revenue stream is Trogarzo. Understanding this composition is critical for investors evaluating how THTX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Theratechnologies Inc maintains a gross margin of 73.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3.07%, while the net margin is -25.17%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively THTX converts its operational activities into shareholder value.

In the context of the broader market, THTX competes directly with industry leaders such as ACRS and TLSA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, THTX's gross margin of 73.50% stands against ACRS's 10.80% and TLSA's N/A. Such benchmarking helps identify whether Theratechnologies Inc is trading at a premium or discount relative to its financial performance.